Peter is a leader in McKinsey's Global Biopharmaceuticals Practice, and previously the head of
the New Jersey office. Over a 20-year McKinsey career, Peter has dedicated himself to helping
leading companies in the pharmaceutical and medical products industries achieve their goals
and stay competitive. He has served clients in the US, across Europe, and in Japan and China.
He is currently leading the Firm's biopharma advanced analytics (Quantum Black) team in North
Peter partners with biopharmaceutical companies to tackle challenges such as developing
company- and business-unit-level strategies, optimizing portfolios, assessing and executing
M&A transactions, and undertaking value-capture initiatives. A former leader of our Clinical
Development Practice, Peter also has a deep understanding of R&D, medical and related
In addition to serving large cap multi-national healthcare companies, Peter has supported a
larger number of biotech companies (small and mid-cap) on Its growth journey, including
portfolio strategy, business development, functional excellence, commercialization and xUS
market entry Initiatives. Peter has also supported various industry collaborations and
associations, including BIO, DIA, CPath and other.
Peter began his McKinsey career in 1995 (in New Jersey since 2000). He holds a masters and
PhD degree from University of St Gallen. Prior to McKinsey, Peter worked in finance roles in
Korea, China and the US.